XENE
Xenon Pharmaceuticals Inc
36.60$
-6.5%
vs. previous close
Closing price · As of: Sep 23, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 97.2% | 95.2% | 97.3% | 97.2% | 99.2% | 98.1% | 96.1% | 97.7% | 79.6% | 66.8% | 79.6% | 57.1% | |
| 82.4% | 91.7% | 25.3% | 44.4% | 55.3% | 16.8% | 23.8% | 30.7% | 7.6% | 15.4% | 17.9% | 20.3% | |
| 96.1% | 91.7% | 95.0% | 94.7% | 97.4% | 95.7% | 93.6% | 96.5% | 78.5% | 66.1% | 78.5% | 55.9% | |
| 0.2% | 0.5% | 0.3% | 0.9% | 0.2% | 0.6% | 1.0% | 0.5% | 0.1% | 0.1% | 0.2% | 0.1% | |
| 0.0% | -0.5% | 0.0% | 0.0% | – | – | -1.0% | -0.5% | -0.1% | 0.0% | – | – | |
| 2.8% | 3.1% | 2.1% | 2.3% | 0.8% | 1.1% | 1.9% | 0.8% | 0.9% | – | – | – | |
| 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | – | – | |
| 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | – | – | |
| 16.7% | 4.6% | 5.3% | 22.1% | 15.6% | 37.7% | 9.4% | 3.8% | 4.3% | 3.8% | 5.4% | 40.7% | |
| 16.3% | 4.4% | 5.2% | 8.9% | 3.4% | 29.4% | 7.8% | 2.5% | 3.0% | 2.8% | 4.5% | 4.3% | |
| – | – | – | 1.5% | 12.3% | 3.3% | 0.1% | 0.1% | 0.1% | 0.1% | 0.2% | 0.2% | |
| 0.6% | 1.7% | 2.2% | 2.7% | 0.5% | 1.7% | 1.6% | 0.7% | 1.1% | 0.9% | 0.6% | 0.4% | |
| 0.0% | 0.0% | 0.0% | 13.2% | 12.3% | 7.4% | – | – | – | – | – | – | |
| 83.3% | 95.4% | 94.7% | 77.9% | 84.4% | 62.3% | 90.6% | 96.2% | 95.7% | 96.2% | 94.6% | 59.3% | |
| -118.7% | -187.2% | -211.4% | -375.9% | -169.8% | -169.0% | -147.2% | -62.5% | -64.0% | -68.9% | -112.7% | -126.9% | |
| 15.9% | 22.3% | 23.0% | 39.0% | 15.9% | 17.6% | 18.3% | 7.6% | 8.0% | 6.9% | 9.8% | 8.1% |
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.